Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells

Aldo Maria Roccaro, Teru Hideshima, Noopur Raje, Shaji Kumar, Kenji Ishitsuka, Hiroshi Yasui, Norihiko Shiraishi, Domenico Ribatti, Beatrice Nico, Angelo Vacca, Franco Dammacco, Paul Gerard Richardson, Kenneth Carl Anderson

Research output: Contribution to journalArticle

220 Citations (Scopus)

Abstract

Bone marrow angiogenesis plays an important role in the pathogenesis and progression in multiple myeloma. Recent studies have shown that proteasome inhibitor bortezomib (Velcade, formerly PS-341) can overcome conventional drug resistance in vitro and in vivo; however, its antiangiogenic activity in the bone marrow milieu has not yet been defined. In the present study, we examined the effects of bortezomib on the angiogenic phenotype of multiple myeloma patient-derived endothelial cells (MMEC). At clinically achievable concentrations, bortezomib inhibited the proliferation of MMECs and human umbilical vein endothelial cells in a dose-dependent and time-dependent manner. In functional assays of angiogenesis, including chemotaxis, adhesion to fibronectin, capillary formation on Matrigel, and chick embryo chorioallantoic membrane assay, bortezomib induced a dose-dependent inhibition of angiogenesis. Importantly, binding of MM.1S cells to MMECs triggered multiple myeloma cell proliferation, which was also abrogated by bortezomib in a dose-dependent fashion. Bortezomib triggered a dose-dependent inhibition of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) secretion by the MMECs, and reverse transcriptase-PCR confirmed drug-related down-regulation of VEGF, IL-6, insulin-like growth factor-I, Angiopoietin 1 (Ang1), and Ang2 transcription. These data, therefore, delineate the mechanisms of the antiangiogenic effects of bortezomib on multiple myeloma cells in the bone marrow milieu.

Original languageEnglish
Pages (from-to)184-191
Number of pages8
JournalCancer Research
Volume66
Issue number1
DOIs
Publication statusPublished - Jan 1 2006

Fingerprint

Multiple Myeloma
Endothelial Cells
Vascular Endothelial Growth Factor A
Interleukin-6
Bone Marrow
Angiopoietin-1
Bortezomib
Chorioallantoic Membrane
Proteasome Inhibitors
Human Umbilical Vein Endothelial Cells
Chemotaxis
Chick Embryo
Reverse Transcriptase Polymerase Chain Reaction
Insulin-Like Growth Factor I
Fibronectins
Drug Resistance
Bone Marrow Cells
Down-Regulation
Cell Proliferation
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Roccaro, A. M., Hideshima, T., Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., ... Anderson, K. C. (2006). Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Research, 66(1), 184-191. https://doi.org/10.1158/0008-5472.CAN-05-1195

Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. / Roccaro, Aldo Maria; Hideshima, Teru; Raje, Noopur; Kumar, Shaji; Ishitsuka, Kenji; Yasui, Hiroshi; Shiraishi, Norihiko; Ribatti, Domenico; Nico, Beatrice; Vacca, Angelo; Dammacco, Franco; Richardson, Paul Gerard; Anderson, Kenneth Carl.

In: Cancer Research, Vol. 66, No. 1, 01.01.2006, p. 184-191.

Research output: Contribution to journalArticle

Roccaro, AM, Hideshima, T, Raje, N, Kumar, S, Ishitsuka, K, Yasui, H, Shiraishi, N, Ribatti, D, Nico, B, Vacca, A, Dammacco, F, Richardson, PG & Anderson, KC 2006, 'Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells', Cancer Research, vol. 66, no. 1, pp. 184-191. https://doi.org/10.1158/0008-5472.CAN-05-1195
Roccaro, Aldo Maria ; Hideshima, Teru ; Raje, Noopur ; Kumar, Shaji ; Ishitsuka, Kenji ; Yasui, Hiroshi ; Shiraishi, Norihiko ; Ribatti, Domenico ; Nico, Beatrice ; Vacca, Angelo ; Dammacco, Franco ; Richardson, Paul Gerard ; Anderson, Kenneth Carl. / Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. In: Cancer Research. 2006 ; Vol. 66, No. 1. pp. 184-191.
@article{89b579ec7ffe4e408aff84381e985bf8,
title = "Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells",
abstract = "Bone marrow angiogenesis plays an important role in the pathogenesis and progression in multiple myeloma. Recent studies have shown that proteasome inhibitor bortezomib (Velcade, formerly PS-341) can overcome conventional drug resistance in vitro and in vivo; however, its antiangiogenic activity in the bone marrow milieu has not yet been defined. In the present study, we examined the effects of bortezomib on the angiogenic phenotype of multiple myeloma patient-derived endothelial cells (MMEC). At clinically achievable concentrations, bortezomib inhibited the proliferation of MMECs and human umbilical vein endothelial cells in a dose-dependent and time-dependent manner. In functional assays of angiogenesis, including chemotaxis, adhesion to fibronectin, capillary formation on Matrigel, and chick embryo chorioallantoic membrane assay, bortezomib induced a dose-dependent inhibition of angiogenesis. Importantly, binding of MM.1S cells to MMECs triggered multiple myeloma cell proliferation, which was also abrogated by bortezomib in a dose-dependent fashion. Bortezomib triggered a dose-dependent inhibition of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) secretion by the MMECs, and reverse transcriptase-PCR confirmed drug-related down-regulation of VEGF, IL-6, insulin-like growth factor-I, Angiopoietin 1 (Ang1), and Ang2 transcription. These data, therefore, delineate the mechanisms of the antiangiogenic effects of bortezomib on multiple myeloma cells in the bone marrow milieu.",
author = "Roccaro, {Aldo Maria} and Teru Hideshima and Noopur Raje and Shaji Kumar and Kenji Ishitsuka and Hiroshi Yasui and Norihiko Shiraishi and Domenico Ribatti and Beatrice Nico and Angelo Vacca and Franco Dammacco and Richardson, {Paul Gerard} and Anderson, {Kenneth Carl}",
year = "2006",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-05-1195",
language = "English",
volume = "66",
pages = "184--191",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells

AU - Roccaro, Aldo Maria

AU - Hideshima, Teru

AU - Raje, Noopur

AU - Kumar, Shaji

AU - Ishitsuka, Kenji

AU - Yasui, Hiroshi

AU - Shiraishi, Norihiko

AU - Ribatti, Domenico

AU - Nico, Beatrice

AU - Vacca, Angelo

AU - Dammacco, Franco

AU - Richardson, Paul Gerard

AU - Anderson, Kenneth Carl

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Bone marrow angiogenesis plays an important role in the pathogenesis and progression in multiple myeloma. Recent studies have shown that proteasome inhibitor bortezomib (Velcade, formerly PS-341) can overcome conventional drug resistance in vitro and in vivo; however, its antiangiogenic activity in the bone marrow milieu has not yet been defined. In the present study, we examined the effects of bortezomib on the angiogenic phenotype of multiple myeloma patient-derived endothelial cells (MMEC). At clinically achievable concentrations, bortezomib inhibited the proliferation of MMECs and human umbilical vein endothelial cells in a dose-dependent and time-dependent manner. In functional assays of angiogenesis, including chemotaxis, adhesion to fibronectin, capillary formation on Matrigel, and chick embryo chorioallantoic membrane assay, bortezomib induced a dose-dependent inhibition of angiogenesis. Importantly, binding of MM.1S cells to MMECs triggered multiple myeloma cell proliferation, which was also abrogated by bortezomib in a dose-dependent fashion. Bortezomib triggered a dose-dependent inhibition of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) secretion by the MMECs, and reverse transcriptase-PCR confirmed drug-related down-regulation of VEGF, IL-6, insulin-like growth factor-I, Angiopoietin 1 (Ang1), and Ang2 transcription. These data, therefore, delineate the mechanisms of the antiangiogenic effects of bortezomib on multiple myeloma cells in the bone marrow milieu.

AB - Bone marrow angiogenesis plays an important role in the pathogenesis and progression in multiple myeloma. Recent studies have shown that proteasome inhibitor bortezomib (Velcade, formerly PS-341) can overcome conventional drug resistance in vitro and in vivo; however, its antiangiogenic activity in the bone marrow milieu has not yet been defined. In the present study, we examined the effects of bortezomib on the angiogenic phenotype of multiple myeloma patient-derived endothelial cells (MMEC). At clinically achievable concentrations, bortezomib inhibited the proliferation of MMECs and human umbilical vein endothelial cells in a dose-dependent and time-dependent manner. In functional assays of angiogenesis, including chemotaxis, adhesion to fibronectin, capillary formation on Matrigel, and chick embryo chorioallantoic membrane assay, bortezomib induced a dose-dependent inhibition of angiogenesis. Importantly, binding of MM.1S cells to MMECs triggered multiple myeloma cell proliferation, which was also abrogated by bortezomib in a dose-dependent fashion. Bortezomib triggered a dose-dependent inhibition of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) secretion by the MMECs, and reverse transcriptase-PCR confirmed drug-related down-regulation of VEGF, IL-6, insulin-like growth factor-I, Angiopoietin 1 (Ang1), and Ang2 transcription. These data, therefore, delineate the mechanisms of the antiangiogenic effects of bortezomib on multiple myeloma cells in the bone marrow milieu.

UR - http://www.scopus.com/inward/record.url?scp=31544433927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544433927&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-1195

DO - 10.1158/0008-5472.CAN-05-1195

M3 - Article

VL - 66

SP - 184

EP - 191

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 1

ER -